Weight-loss drug competition heats up with growing pill market

The weight-loss market is heating up as a number of companies are looking for a way to upend the dominance of market leaders Novo Nordisk , Novo, and a smaller biotech prove that an oral option could be as effective as injectables, but Wall Street is waiting to see whether or not patients will prefer a daily pill to a weekly or monthly injectable.

The frontrunner is Lilly's orforglipron, which showed up to 14.7% weight loss in Phase 2 trials at 36 weeks. It has set the bar for other contenders and gives investors confidence in the current injectable market leader's ability to capture market share. Closeup of the big three injectable prescription weight loss medicines: Ozempic, Victoza, and Wegovy.

Dr. Michael Weintraub, an endocrinologist and obesity medicine specialist at NYU Langone Health in New York City, says that competition is necessary because all patients are not the same.

Belgique Dernières Nouvelles, Belgique Actualités

Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.

GLP-1 use cases are growing: What it means for pharma stocksSharess of Eli Lilly are moving higher on Tuesday after the company revealed that a recent study, conducted by the company, showed that its weight-loss drug ...
La source: YahooFinanceCA - 🏆 47. / 63 Lire la suite »

Retail earnings and the consumer, GLP-1 stocks : Market DominationIt's that time of the day again — the final hour of trading — which means it's time for Market Domination with Julie Hyman and Josh Lipton as they cover the ...
La source: YahooFinanceCA - 🏆 47. / 63 Lire la suite »